BioCentury
ARTICLE | Clinical News

ME-143: Phase I data

June 11, 2012 7:00 AM UTC

An open-label, U.S. Phase I trial in 15 patients with refractory solid tumors showed that once-weekly 2.5, 5, 10 and 20 mg/kg doses of IV ME-143 were generally well tolerated with 1 serious infusion r...